Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

EYPT
EyePoint, Inc. Common Stock
stock NASDAQ

At Close
Jul 14, 2026 3:59:58 PM EDT
13.75USD-3.711%(-0.53)1,039,904
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 14, 2026 9:10:30 AM EDT
14.47USD+1.331%(+0.19)2,829
After-hours
Jul 14, 2026 4:59:30 PM EDT
13.65USD-0.727%(-0.10)2,000
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
08:00AM EST  Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting   GlobeNewswire Inc
07:00AM EST  EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief   GlobeNewswire Inc
Dec 15, 2021
08:00AM EST  Aramis Biosciences Launches to Address Unmet Needs in Ocular   GlobeNewswire Inc
Dec 8, 2021
08:19AM EST  The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom   Benzinga
Dec 7, 2021
04:32PM EST  EyePoint Pharma Reports Expanded US Commercial Alliance For DEXYCU With Harrow Health   Benzinga
04:32PM EST  EyePoint Pharmaceuticals and Harrow Healths   GlobeNewswire Inc
Nov 23, 2021
08:22AM EST  EyePoint Granted U.S. Patent Titled 'Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)'   Benzinga
Nov 19, 2021
12:33PM EST  EyePoint Pharmaceuticals Announces Closing of $115.4 Million   GlobeNewswire Inc
Nov 17, 2021
02:39PM EST  Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher   Benzinga
12:15PM EST  Mid-Day Market Update: StoneCo Drops After Q3 Earnings; EyePoint Pharmaceuticals Shares Surge   Benzinga
10:12AM EST  Mid-Morning Market Update: Markets Down; Lowe's Earnings Beat Estimates   Benzinga
07:53AM EST  The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment   Benzinga
Nov 16, 2021
11:18PM EST  EyePoint Pharmaceuticals Announces Pricing of Public Offering   GlobeNewswire Inc
04:33PM EST  EyePoint Pharma Reports $100M Common Stock Offering   Benzinga
04:32PM EST  EyePoint Pharmaceuticals Announces Proposed Public Offering of   GlobeNewswire Inc
Nov 15, 2021
10:53AM EST  Eyepoint Pharmaceuticals Shares Spike to Premarket Highs; Co on Saturday Announced Wet AMD Trial Results Showed 76% and 53% of Patients Were Rescue-free Up to Four & Six Months, Respectively, After Single Injection of EYP-1901   Benzinga
10:51AM EST  HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $24   Benzinga
Nov 13, 2021
11:29AM EST  EyePoint Pharmaceuticals Inc. (EYPT) announced positive interim safety and efficacy data from phase 1 DAVIO clinical trial evaluating EYP-1901 for the Treatment of wet age-related macular degeneration.   RTTNews
10:51AM EST  EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from   PR Newswire
Nov 11, 2021
07:00AM EST  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at two upcoming virtual conferences:   GlobeNewswire Inc
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
Nov 5, 2021
09:39AM EDT  EyePoint Pharmaceuticals To Host Conference Call Highlighting Interim Phase 1 Clinical Data From Ongoing DAVIO Trial Of EYP-1901 For Wet AMD   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals to Host Conference Call Highlighting   GlobeNewswire Inc
Nov 3, 2021
09:16AM EDT  EyePoint Pharmaceuticals Q3 EPS $(0.58) Misses $(0.40) Estimate, Sales $9.06M Miss $9.84M Estimate   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
07:00AM EDT  Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS)   GlobeNewswire Inc
Nov 1, 2021
07:55AM EDT  EyePoint Pharmaceuticals, Inc. (EYPT), a company which develops therapeutics to cure serious eye disorders, on Monday said it has appointed Jay Duker as Chief Operating Officer or COO.   RTTNews
07:31AM EDT  EyePoint Pharma Announces Positive Interim Safety Data From Phase 1 DAVIO Trial In Eyes With Wet AMD   RTTNews
07:17AM EDT  EyePoint Pharma Appoints Jay Duker As COO   RTTNews
07:09AM EDT  EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. As Chief Operating Officer   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals AppointsJay S. Duker, M.D. as   GlobeNewswire Inc
Oct 27, 2021
07:00AM EDT  EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial   GlobeNewswire Inc
Oct 12, 2021
03:01PM EDT  EyePoint Pharma Highlights Presentation Of Prelim. Data From Phase 1 DAVIO Trial, YUTIQ CALM Registry Study At American Society Of Retina Specialists Meeting   Benzinga
03:00PM EDT  3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD   GlobeNewswire Inc
Oct 7, 2021
12:53PM EDT  EyePoint Pharma Sponsored Study Titled 'A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye' Posted To ClinicalTrials.gov   Benzinga
Sep 30, 2021
12:24PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Nancy Lurker Says Co's Technology Can Only Deliver Small Molecules, Not Something As Large As An Antibody   Benzinga
12:22PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Nancy Lurker Says Has $1267.6M In Cash As Of June, 2021   Benzinga
12:21PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Highlights Data From 30-Day Safety Study   Benzinga
12:19PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Nancy Lurker Says Plans To Read Out EYP-1901 Data At 6-Months Efficacy   Benzinga
12:16PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Highlights Use Of EYP-1901 On VEGF Signaling Pathways   Benzinga
12:11PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Says Co Has 'A Few' Undisclosed Pre-Clinical Products   Benzinga
12:10PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Nancy Lurker Says Co Has 4 FDA-Approved Products   Benzinga
12:09PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Highlights Positive, Previously-Announced Q2 Product Revenue   Benzinga
12:07PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Nancy Lurker Highlights Suite Of Drugs, Including EYP-1901 And YUTIQ50   Benzinga
12:06PM EDT  From BZ's Small Cap Healthcare Conference: EyePoint Pharmaceuticals CEO Nancy Lurker Begins Presentation   Benzinga
10:19AM EDT  EyePoint Sets its Sights on Developing Treatments Improving the Lives of Eye Disease Sufferers   Benzinga
Sep 17, 2021
07:09AM EDT  EyePoint Pharma Reports Will Present Data At American Academy Of Ophthalmology Meeting   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals to Present Data at the American Academy   GlobeNewswire Inc
Sep 14, 2021
07:52AM EDT  EyePoint Sets its Sights on Continued Trial Success in Developing Treatments Improving the Lives of Eye Disorder Sufferers   Benzinga
Sep 7, 2021
07:00AM EDT  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals senior management team will present at the following four upcoming conferences:   GlobeNewswire Inc
Aug 10, 2021
07:00AM EDT  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021.   GlobeNewswire Inc
Aug 4, 2021
07:43AM EDT  EyePoint Pharmaceuticals Q2 EPS $(0.35) Beats $(0.43) Estimate, Sales $8.70M Miss $9.13M Estimate   Benzinga
07:00AM EDT  Positive 30-Day Safety Data Reported for EYP-1901 DAVIO study for the potential treatment of wet AMD; study remains on track for initial readout in Q4 2021   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 4, 2021   Benzinga
Aug 2, 2021
07:00AM EDT  EyePoint Pharmaceuticals Announces Renowned Scientists to Join New   GlobeNewswire Inc
Jul 28, 2021
08:00AM EDT  EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial   GlobeNewswire Inc
Jul 20, 2021
07:08AM EDT  EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company expects to receive a nine month extension on DEXYCUs pass-through payment status, which otherwise would expire on March 31, 2022.   GlobeNewswire Inc
Jul 6, 2021
07:20AM EDT  EyePoint Pharma Reports Positive 30-day Safety Results For All Cohorts From The DAVIO Trial Of EYP-1901 For Wet-AMD   RTTNews
07:06AM EDT  EyePoint Pharmaceuticals Reports 30-day Safety Results For All Cohorts From DAVIO Trial Of EYP-1901 For wet-AMD; Report sNo Serious Adverse Events   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals Reports Positive 30-day Safety Results   GlobeNewswire Inc
Jul 1, 2021
07:07AM EDT  EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU Intraocular Suspension, Approved by the American Medical Association   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals Announces New Category III CPT Code for   GlobeNewswire Inc
Jun 28, 2021
07:12AM EDT  EyePoint Pharma Announces Joining the Russell 2000 and Russell 3000   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals Joins Russell 2000 and   GlobeNewswire Inc
Jun 14, 2021
04:27PM EDT  Exclusive: EyePoint Pharmaceuticals CEO, Nancy Lurker To Appear On Benzinga's 'Power Hour' Show At 12:30 p.m. EDT On Tuesday   Benzinga
May 26, 2021
07:00AM EDT  EyePoint Pharmaceuticals to Participate in Fireside Chat at the   GlobeNewswire Inc
May 25, 2021
07:02AM EDT  EyePoint Pharmaceuticals Announces Completion Of Enrollment Of Phase 1 DAVIO Clinical Trial Of EYP-1901 For Potential Treatment Of Wet AMD   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals Announces Completion of Enrollment of   GlobeNewswire Inc
May 6, 2021
06:50AM EDT  HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $15   Benzinga
May 5, 2021
08:03AM EDT  EyePoint Pharmaceuticals: Q1 Earnings Insights   Benzinga
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
07:22AM EDT  EyePoint Pharmaceuticals Reports Q1 2021 Net Product Revenue For YUTIQ Was $3M; Net Product Revenue For DEXYCU Was $3.8M   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals Reports First Quarter 2021 Financial   GlobeNewswire Inc
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
May 4, 2021
10:35AM EDT  EyePoint Pharmaceuticals's Earnings Outlook   Benzinga
Apr 28, 2021
07:00AM EDT  EyePoint Pharmaceuticals to Report First Quarter 2021 Financial   GlobeNewswire Inc
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
07:20AM EST  EyePoint Pharmaceuticals Q2 EPS $(1.07) Down From $(0.98) YoY, Sales $7.13M Down From $8.63M YoY   Benzinga
07:00AM EST  EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020   GlobeNewswire Inc
04:07AM EST  Earnings Scheduled For March 4, 2021   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 25, 2021
07:00AM EST  EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year   GlobeNewswire Inc
Feb 4, 2021
12:29PM EST  EyePoint Pharmaceuticals Announces Closing of $115 Million Public   GlobeNewswire Inc
Feb 2, 2021
08:48AM EST  EyePoint Pharma Prices $100M Equity Offering At $11 A Piece   Benzinga
08:05AM EST  The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment   Benzinga
12:11AM EST  EyePoint Pharma Prices Public Offering Of 9.1 Mln Shares At $11/Shr   RTTNews
Feb 1, 2021
10:18PM EST  EyePoint Pharmaceuticals Announces Pricing of Public Offering of   GlobeNewswire Inc
04:03PM EST  EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock; No Terms Disclosed   Benzinga
04:01PM EST  EyePoint Pharmaceuticals Announces Proposed Public Offering of   GlobeNewswire Inc
Jan 28, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2021   Benzinga
07:11AM EST  EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD   Benzinga
07:04AM EST  Cantor Fitzgerald Initiates Coverage On EyePoint Pharmaceuticals with Overweight Rating, Announces Price Target of $22   Benzinga
07:00AM EST  EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1   GlobeNewswire Inc
Jan 27, 2021
04:04PM EST  Cantor Fitzgerald Initiates Coverage On EyePoint Pharmaceuticals with Overweight Rating, Announces Price Target of $22   Benzinga
Jan 22, 2021
06:15AM EST  EyePoint Pharma 13D Filing From Ocumension Therapeutics Shows 16.6% Stake In Co.   Benzinga
Jan 11, 2021
04:07PM EST  EyePoint Pharmaceuticals Sees Q4 Sales $6.2M-$6.6M, FY20 Sales $20.3M-$20.7M   Benzinga
04:01PM EST  - IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitrealanti-VEGF treatment targeting wet age-related macular degeneration -   GlobeNewswire Inc
Jan 3, 2021
07:53PM EST  EyePoint Pharmaceuticals Inc. (EYPT) said that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company, has made a $15.7 million equity investment in EyePoint.   RTTNews
07:00PM EST  EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment   GlobeNewswire Inc
Dec 18, 2020
07:23AM EST  EyePoint Announces Royalty Monetization Agreement With SWK Holdings   RTTNews
07:01AM EST  EyePoint Pharmaceuticals Announces $16.5M Royalty Monetization Agreement For ILUVIEN Royalty With SWK Holdings Corporation   Benzinga
07:00AM EST  EyePoint Pharmaceuticals Announces $16.5 Million Monetization of   GlobeNewswire Inc
Dec 8, 2020
09:22AM EST  EyePoint Pharmaceuticals Announces 1-For-10 Reverse Stock Split   Benzinga
Dec 3, 2020
07:12AM EST  EyePoint Pharma Announces Positive Results From Good Laboratory Practice Preclinical Toxicology Study Of EYP-1901   RTTNews
07:00AM EST  EyePoint Pharmaceuticals Reports Positive Results from GLP   GlobeNewswire Inc
Nov 19, 2020
07:00AM EST  EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual   GlobeNewswire Inc
Nov 16, 2020
07:10AM EST  EyePoint Pharmaceuticals Presents Positive Data of YUTIQ and DEXYCU in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting   Benzinga
07:00AM EST  -Second Phase 3 trial of YUTIQconfirms 36-monthpositive efficacyresults from the   GlobeNewswire Inc
Nov 10, 2020
07:00AM EST  EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that four abstracts featuring YUTIQ and DEXYCU have been selected for presentation at the upcoming American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting, taking place November 13-15, 2020.   GlobeNewswire Inc
Nov 5, 2020
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
07:26AM EST  EyePoint Pharmaceuticals Q1 EPS $(0.03) Beats $(0.05) Estimate, Sales $15.70M Beat $10.54M Estimate   Benzinga
07:00AM EST  - Total revenues of $15.7 million and net product revenues of $5.8 million -   GlobeNewswire Inc
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 29, 2020
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter 2020 on Thursday, November 5, 2020. Management will host a conference call to review the results at 8:30 AM ET on the same day.   GlobeNewswire Inc
Oct 27, 2020
08:25AM EDT  The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings   Benzinga
Oct 9, 2020
09:32AM EDT  Benzinga's Top Upgrades, Downgrades For October 9, 2020   Benzinga
06:45AM EDT  HC Wainwright & Co. Upgrades EyePoint Pharmaceuticals to Buy, Announces $2 Price Target   Benzinga
Oct 8, 2020
07:09AM EDT  EyePoint Pharmaceuticals Announces Amendment To CRG Debt Facility Modifying 2020 And 2021 Revenue Covenants; Co. Says Had ~$28.7M In Cash As Of Sept. 30   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility   GlobeNewswire Inc
Oct 7, 2020
07:11AM EDT  EyePoint Pharma Sees Q3 Net Product Revenues Of Between $5.5 - $5.9 Mln   RTTNews
07:07AM EDT  EyePoint Pharmaceuticals Sees Prelim. Q3 Net Product Revenues $5.5M-$5.9M   Benzinga
07:00AM EDT  - Q3 2020 net product revenues are estimated to be between $5.5- $5.9million, ashealthcare facilities began reopening from COVID-19 closures -   GlobeNewswire Inc
Aug 26, 2020
11:51AM EDT  Insider Buys EyePoint Pharmaceuticals's Shares   Benzinga
Aug 24, 2020
07:16AM EDT  EyePoint Pharmaceuticals Secures New Purchase And Marketing Agreement With Vantage Outsourcing For DEXYCU   Benzinga
07:12AM EDT  EyePoint Pharma Secures New Purchase And Marketing Agreement With Vantage Outsourcing For DEXYCU   RTTNews
07:00AM EDT  EyePoint Pharmaceuticals Secures New Purchase and Marketing   GlobeNewswire Inc
Aug 20, 2020
07:03AM EDT  EyePoint Pharmaceuticals Receives $9.5M In Upfront Cash From Ocumension Therapeutics Under Expanded License Agreements   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash   GlobeNewswire Inc
Aug 13, 2020
08:18AM EDT  The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller   Benzinga
Aug 5, 2020
08:19AM EDT  EyePoint Pharmaceuticals: Q4 Earnings Insights   Benzinga
08:06AM EDT  EyePoint Pharmaceuticals Q4 EPS $(0.10), Inline, Sales $4.12M Beat $3.73M Estimate   Benzinga
07:00AM EDT  - Total revenues of$4.1 millionand net product revenues of$3.7 million impacted by COVID-19 pandemic -   GlobeNewswire Inc
04:21AM EDT  Earnings Scheduled For August 5, 2020   Benzinga
Aug 4, 2020
07:13AM EDT  EyePoint Pharmaceuticals And Harrow Health's ImprimisRx Announce US Commercial Alliance For DEXYCU   Benzinga
07:00AM EDT  EyePoint Pharmaceuticals and Harrow Healths   GlobeNewswire Inc
Jul 29, 2020
07:00AM EDT  EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020. Management will host a conference call to review the results at 8:30 AM ET on the same day.   GlobeNewswire Inc
Jul 27, 2020
07:00AM EDT  EyePoint Pharmaceuticals Presents Data Supporting   GlobeNewswire Inc
Jul 13, 2020
07:00AM EDT  - World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoints ocular disease pipeline -   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC